These data suggested that TAC-induced reduction of the β-catenin/TCF7L2 pathway might be associated with the targeted mechanism of EMPA, which reduces the primary composite endpoint of major adverse cardiovascular events, cardiovascular death, and hospitalization rate for HF, as observed in EMPA-REGOUTCOME trial. Here, TCF7L2 is linked to hydrops fetalis.